Form 4: Doximity Director Granted 3,221 RSUs as Compensation

Doximity, Inc. director Phoebe L. Yang received a grant of 3,221 restricted stock units as part of the company's non-employee director compensation policy.

Summary

• Director Phoebe L. Yang was granted 3,221 Restricted Stock Units (RSUs) of Doximity, Inc. Class A Common Stock on August 28, 2025.
• The grant is part of the company's non-employee director compensation policy and was reported on September 2, 2025.
• These RSUs vest in full on the earlier of August 28, 2026 (the first anniversary of the grant date) or the Issuer's next annual meeting of stockholders.
• Vesting is contingent upon Ms. Yang's continued service as a director through the applicable vesting date.
• Following this transaction, Ms. Yang directly beneficially owns 17,950 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: Neutral to slightly positive. This is a routine compensation event for a director, indicating standard corporate governance and alignment of interests, but does not reflect operational performance or significant strategic shifts.

Positives

• The grant of RSUs aligns the director's interests with shareholders, promoting long-term commitment and performance.
• The existence of a non-employee director compensation policy indicates structured corporate governance practices.

Risks

• The vesting of the 3,221 RSUs is subject to the director's continued service, meaning the shares are not guaranteed if service ceases before the vesting date.

Future Outlook

The 3,221 Restricted Stock Units are scheduled to vest in full on the earlier of August 28, 2026, or the Issuer's next annual meeting of stockholders, contingent on the director's continued service.

Industry Context

This is a standard compensation practice for non-employee directors in publicly traded companies, aiming to align their interests with long-term shareholder value. It reflects a common approach to executive and director remuneration in the healthcare technology sector.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as part of non-employee director compensation is a common practice across the technology and healthcare sectors, similar to companies like Teladoc Health (TDOC) or Veeva Systems (VEEV), which frequently use equity to incentivize long-term commitment.
• The vesting schedule, tied to continued service and an annual cycle, is standard for such grants, aligning with practices observed at peer companies in the industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Director's interests are further aligned with long-term shareholder value through equity ownership.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The 3,221 RSUs will vest on the earlier of August 28, 2026, or the Issuer's next annual meeting of stockholders, subject to continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a non-employee director as part of their compensation. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It simply reflects standard corporate governance and director incentive alignment.

Keywords

Doximity, DOCS, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Equity Grant, Corporate Governance